BPC-157/TB-500 Wolverine

Description

BPC-157 / TB-500 – Regenerative Peptide Combination

What is BPC-157 / TB-500?

BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) are synthetic peptides that work synergistically to promote tissue repair, angiogenesis, and cellular regeneration. Widely investigated in regenerative medicine, sports medicine, and tissue engineering, these peptides have demonstrated potent wound-healing and anti-inflammatory properties in preclinical studies.

Summary Table

Mechanism of Action

• BPC-157

  • Stimulates angiogenesis through upregulation of Vascular Endothelial Growth Factor (VEGF).

  • Enhances fibroblast migration and collagen deposition for tendon/ligament repair.

  • Exerts cytoprotective effects in the gastrointestinal tract via nitric oxide modulation.

  • Provides neuroprotective activity by supporting dopaminergic and serotonergic signaling.

• TB-500

  • Mimics the activity of Thymosin Beta-4 by regulating the actin cytoskeleton, enabling cell migration and tissue regeneration.

  • Promotes angiogenesis and vasodilation for improved blood supply to injured tissues.

  • Enhances wound repair in skin, muscle, and cardiac tissues.

  • Exhibits anti-fibrotic effects by reducing scar tissue formation.

Together, BPC-157 + TB-500 create a synergistic regenerative effect, targeting both structural repair (BPC-157) and cellular dynamics/angiogenesis (TB-500).

Research Applications

• Orthopedics & Sports Medicine – Acceleration of tendon, ligament, and muscle recovery.

• Cardiology – Potential applications in post-myocardial infarction tissue repair.

• Neurology – Neuroprotection and axonal regeneration in preclinical models.

• Gastroenterology – BPC-157 for ulcer healing, intestinal protection, and inflammatory bowel disease.

• Dermatology & Plastic Surgery – Wound healing, scar reduction, and skin regeneration.

• Experimental Regenerative Therapies – Combination use in trauma, post-surgical healing, and tissue engineering.

Safety & Tolerability

• BPC-157: Preclinical animal studies suggest high tolerability, no significant systemic toxicity reported.

• TB-500: Demonstrated safety in animal and limited human use, though systemic angiogenesis warrants further research.

• Combination Therapy: The synergistic effect is promising, but clinical validation in humans remains limited.

Commonly Reported Effects in Research Settings:

• Enhanced tissue repair rates.

• Increased angiogenesis at injury sites.

• Reduced inflammation.

• Minimal adverse effects observed in preclinical models.

📌 Disclaimer: BPC-157 and TB-500 are research peptides, not approved by the FDA/EMA for medical use. Data primarily derived from animal studies and early experimental trials.

Explore our complete catalog of high-purity, third-party tested research compounds by visiting our main shop page for all your laboratory needs.